Company profile
MacroGenics, Inc.
NASDAQ: MGNX · Healthcare · Biotechnology
#309 of 1,418 Healthcare companies by revenue40th-percentile growth
EA Score
54DFH 46DQ 69GM 41SS 68
v0.1 · 65/100 weight · provisional
↑ disclosure history, workforce scale · ↓ return on equity, balance-sheet leverage
Methodology →Revenue TTM
$157.1M
Rev growth YoY (TTM)
+3.1%
Net income (FY)
-$74.6M
Employees
293
as of 2026-08-13
Market cap
$255.5M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$149.5M$149.5M2025
Net income-$74.6M-$74.6M2025
Operating income-$72.8M-$72.8M2025
Total assets$256.8M$256.8M2025
Liabilities$201.3M$201.3M2025
Equity$55.6M$55.6M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Revenue From Collaborative Agreements62%
Contract Manufacturing38%
By geography
Not disclosed.
The read
What is MacroGenics, Inc.’s revenue?
MacroGenics, Inc. booked $149.5M in FY2025 revenue, contracting 0.3% year over year — about the middle of the pack among Healthcare companies we track, at a -49.9% net margin.
Peers · Healthcare
Liquidia Corporation58CHeron Therapeutics, Inc.58CAirSculpt Technologies, Inc.58CNeuronetics, Inc.59CElite Pharmaceuticals, Inc.77B+GRAIL Inc.51DNeighbors
Montgomery →Key facts
CEOEric Risser
SectorHealthcare
IndustryBiotechnology
HeadquartersRockville, MD
ExchangeNASDAQ: MGNX
Employees293
IPO date2013-10-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.